Source: K2 Gold Corporation
  • K2 Gold Corporation (KTO) has closed a non-brokered private placement financing
  • The company issued a total of 23,976,500 units at a price of C$0.15 per unit for gross proceeds of C$3,596,475
  • K2 plans to use the net proceeds for exploration and advancement work on its Si2 Gold Project located in Esmeralda County, Nevada, USA
  • K2 Gold Corporation is a member of Discovery Group based in Vancouver, Canada and currently has projects in Southwest USA and the Yukon
  • K2 Gold Corporation opened trading at $0.165

K2 Gold Corporation (KTO) has closed its previously-announced non-brokered private placement for gross proceeds of C$3,596,475.

The company issued a total of 23,976,500 units at a price of C$0.15 per unit. Each unit consists of one common share in the capital of the company and one-half of one non-transferable common share purchase warrant. Each warrant will be exercisable to acquire one share at a price of C$0.30 per share for a period until February 1, 2025.

K2 plans to use the net proceeds for exploration and advancement work on the company’s Si2 Gold Project located in Esmeralda County, Nevada, ongoing permitting at the Mojave project, as well as for general working capital.

Insiders of the company acquired an aggregate of 1,033,667 common shares in the offering.

The Si2 Gold Project is located approximately 60km northwest of Tonopah, Nevada, and 20km northwest of Allegiant Gold’s Eastside deposit (1.4Moz Au, 8.8 Moz Ag).

K2 Gold Corporation is a member of Discovery Group based in Vancouver, Canada and currently has projects in Southwest USA and the Yukon.

K2 Gold Corporation opened trading at $0.165.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.